Last reviewed · How we verify

Use of MEOPA during suturing

Centre Hospitalier Universitaire de Nīmes · FDA-approved active Small molecule Quality 2/100

Use of MEOPA during suturing is a Small molecule drug developed by Centre Hospitalier Universitaire de Nīmes. It is currently FDA-approved. Also known as: equimolar mixture of nitrous oxide and oxygen.

At a glance

Generic nameUse of MEOPA during suturing
Also known asequimolar mixture of nitrous oxide and oxygen
SponsorCentre Hospitalier Universitaire de Nīmes
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Use of MEOPA during suturing

What is Use of MEOPA during suturing?

Use of MEOPA during suturing is a Small molecule drug developed by Centre Hospitalier Universitaire de Nīmes.

Who makes Use of MEOPA during suturing?

Use of MEOPA during suturing is developed and marketed by Centre Hospitalier Universitaire de Nīmes (see full Centre Hospitalier Universitaire de Nīmes pipeline at /company/centre-hospitalier-universitaire-de-n-mes).

Is Use of MEOPA during suturing also known as anything else?

Use of MEOPA during suturing is also known as equimolar mixture of nitrous oxide and oxygen.

What development phase is Use of MEOPA during suturing in?

Use of MEOPA during suturing is FDA-approved (marketed).

Related